Paul Demarco
Rheumatology · Wheaton, MDNPI 1780630954
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AbbVie at 40.0% of the total. Reporting peaked in 2019 at $45,706 and has fallen 99.6% since, to $166 in 2025. Among rheumatology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $490.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- United Rheumatology$29K
- Amgen$15K
- Aurinia Pharma U.S., Inc.$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$896
- plus $1K from 16 others
Across 106 payments — averaging $12,449 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$425K
- Novartis$255K
- AbbVie$241K
- Amgen$177K
- Eli Lilly$136K
- Janssen Research & Development, LLC$73K
- plus $14K from 3 others
What the payments were for
- Consulting fees$28,75035%
- Speaking & faculty fees$42,35952%
- Travel & lodging$6,8338%
- Food & beverage$3,4544%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $32,553 |
| United Rheumatology | 4 | $28,750 |
| Amgen(2 entities) | 25 | $14,832 |
| Aurinia Pharma U.S., Inc. | 4 | $1,557 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,505 |
| Genentech USA, Inc. | 2 | $896 |
| Treace Medical Concepts, Inc. | 8 | $399 |
| Abbott | 1 | $127 |
| Lilly USA, LLC | 5 | $114 |
| UCB, Inc. | 4 | $113 |
| Radius Health, Inc. | 4 | $110 |
| Johnson & Johnson(2 entities) | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Pacira Therapeutics, Inc. | 2 | $73 |
| Pfizer | 4 | $64 |
| GSK | 3 | $59 |
| Novartis | 2 | $43 |
| Merck | 2 | $36 |
| Gilead | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$17,365
- Enbrel$14,420
- Humira$7,071
- KEVZARA$1,484
- Actemra$875
- LUPKYNIS$500
- AMPLATZER$127
- Lapiplasty System$126
- TMC PSI CUT GUIDE SYSTEM$125
- EVENITY$121
How this compares
$81,456 in reported general payments places this provider in the 90th percentile of 173 rheumatology providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 12 | $360 |
| Meloxicam | 13 | $37 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Wheaton
- Herbert BarafWheaton$268K
- Alan MatsumotoWheaton$185K
- Charles OshinskyWheaton$11K
- Evan SiegelRockville$594K
- Donald ThomasGreenbelt$471K
- Edmund MaclaughlinEaston$410K
- Michelle PetriBaltimore$381K
- Elizabeth ClaytonEaston$244K
- Nasser NasseriaslCatonsville$136K
- Marc HochbergBaltimore$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.